Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of HRX215 in Participants After Major Hepatectomy, Preceded by Two Open Pilot Parts in Participants After Minor and After Major Hepatectomy Due to Colon Carcinoma Metastases

NCT06638502 is registered in ClinicalTrials.gov with HepaRegeniX GmbH as lead sponsor.

NCT NCT06638502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06638502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of HRX215 in Participants After Major Hepatectomy, Preceded by Two Open Pilot Parts in Participants After Minor and After Major Hepatectomy Due to Colon Carcinoma Metastases
Lead sponsor
HepaRegeniX GmbH
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 6, 2025
Completion date
December 31, 2027
Enrollment
80 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma liver metastases, liver resection